key: cord-0937466-3k61lesh
authors: Ungaro, Ryan C.; Brenner, Erica J.; Agrawal, Manasi; Zhang, Xian; Kappelman, Michael D.; Colombel, Jean-Frederic; Gearry, Richard B.; Kaplan, Gilaad G.; Kissous-Hunt, Michele; Lewis, James D.; Ng, Siew C.; Rahier, Jean-Francois; Reinisch, Walter; Steinwurz, Flavio
title: Impact of Medications on COVID-19 Outcomes in Inflammatory Bowel Disease: Analysis of Over 6,000 Patients from an International Registry
date: 2021-09-14
journal: Gastroenterology
DOI: 10.1053/j.gastro.2021.09.011
sha: c0e02599c850bc0f554a338dc9b62edcbe71183a
doc_id: 937466
cord_uid: 3k61lesh

nan

Inflammatory Bowel Disease (SECURE-IBD) database, an international, collaborative database created to monitor COVID-19 outcomes in IBD patients, has previously reported that corticosteroids and mesalamine/sulfasalazine are associated with an increased risk of severe COVID-19 while tumor necrosis factor (TNF) antagonists do not impact risk. 1 A follow-up report observed that patients on combination therapy with TNF antagonists and thiopurines appeared to be at higher severe COVID-19 risk. 2 However, at that time the number of reported cases was too low to fully evaluate the risk of other IBD therapies. As the cases reported to SECURE-IBD have increased substantially, more granular analyses evaluating other IBD medication classes (including combination therapies) and adjusting for more covariates are possible. In this study, we compared associations between multiple medication classes and adverse COVID-19 outcomes in the SECURE-IBD database.

We analyzed reports to SECURE-IBD from inception (March 13 th , 2020) through May 21 st , 2021. Details regarding data and analysis are provided in the Supplementary Material. Demographic/clinical characteristics of 6,144 included reports stratified by medication type are provided in Supplementary Table 1 . Figure 1 summarizes the independent associations of medication classes on adverse COVID-19 outcomes among all cases reported to SECURE-IBD. Systemic corticosteroids were associated and methotrexate was marginally associated with an increased odds of hospitalization and/or death.

Medications associated with a decreased odds of COVID-19-related hospitalization and/or death included TNF, interleukin (IL)-12/23, and integrin antagonists. Systemic corticosteroids were significantly associated with increased odds of severe COVID-19, while TNF and IL-12/23 antagonists were associated with a decreased odds of severe COVID-19. Systemic corticosteroids were associated with increased odds of death due to COVID-19, while biologics were not. Notably, there were no statistically significant associations between mesalamine/sulfasalazine and any adverse COVID-19 outcome.

We also observed that TNF antagonist and thiopurine combination therapy was associated with a significant increased risk of hospitalization and/or death ( J o u r n a l P r e -p r o o f Lastly, we restricted our analyses to only patients on biologics (Supplementary Table 2 ).

There was no statistically significant difference in the odds of severe COVID-19 across biologic classes. The proportion of patients who experienced death was similar across biologics. When we included a covariate for mesalamine/sulfasalazine use in models of biologic-treated patients, there was no difference in outcomes with mesalamine/sulfasalazine use compared to non-use (hospitalization and/or death aOR Using a global registry of patients with IBD who developed COVID-19, we evaluated associations between IBD medications and COVID-19 outcomes. The robust number of cases now reported to SECURE-IBD enabled us to perform more granular, analyses than before. Reassuringly, biologics were not associated with more severe COVID-19 outcomes and may have protective effects. Importantly, mesalamine/sulfasalazine does not appear associated with worse COVID-19 outcomes. Combination of TNF antagonists with thiopurines was associated with an increased risk of adverse COVID-19 events, but combination with methotrexate was not.

As in previous SECURE-IBD publications, corticosteroids were associated with increased odds of severe COVID-19 outcomes. 1,2 Although we adjust for physician global assessment in our models, it is an imperfect disease activity measure, and separating the impact of corticosteroids from uncontrolled disease remains challenging. However, the strength and consistency of this signal across immune-mediated inflammatory diseases suggest a true harmful association. [3] [4] [5] J o u r n a l P r e -p r o o f

Our biologic medication analyses substantiate previous studies among patients with immune-mediated inflammatory diseases which found that these therapies are safe to continue during the COVID-19 pandemic. 1, 2, 4, 5 The current findings reinforce prior observations that biologics are not associated with an increased risk of severe COVID-19 outcomes. 2, 6, 7 We also observed that combination therapy of TNF antagonists with thiopurines was associated with higher risk of adverse COVID-19 events compared with TNF antagonist monotherapy. In contrast, combination of TNF antagonists with methotrexate was not significantly associated with any adverse outcome, which is consistent with previous literature on combination therapies and infection risk. 6, 7 Prior SECURE-IBD analyses suggested that mesalamine/sulfasalazine may be associated with increased risk of worse COVID-19 outcomes. This finding appropriately surprised the international gastroenterology community, as 5-ASA is considered a lowrisk medication with minimal systemic effects. 8 Our updated analysis suggests that mesalamine/sulfasalazine is not associated with worse outcomes. Earlier findings were likely due to reporting bias and/or reporting delays, as mild cases of COVID-19 among patients on mesalamine/sulfasalazine may have gone unreported if patients did not alert their IBD provider that they had COVID-19. In contrast, the SECURE-IBD registry may have captured a relatively higher proportion of mild cases among patients on biologics, as these medications require more frequent provider-patient contact. As the pandemic has evolved and testing for COVID-19 has become more widespread, patients with mild COVID-19 symptoms are more likely to be tested and therefore reported to SECURE-J o u r n a l P r e -p r o o f IBD. With increased reporting of mild cases among patients on mesalamine/sulfasalazine, the earlier associations may have attenuated substantially.

Strengths of this study include the global, collaborative nature of the SECURE-IBD registry that includes over 6,000 cases from six continents. However, these data are subject to reporting, confirmation, and recall biases along with residual and/or unmeasured confounding. Patient self-discontinuation of medications could have introduced measurement bias, likely toward the null for higher-risk medications. Finally, although the registry now includes enough patients to adequately power many analyses, some, including those involving tofacitinib and budesonide, remain underpowered.

Overall, these results suggest that many commonly used IBD medications, including biologics and mesalamine/sulfasalazine are not associated with severe COVID-19

outcomes, and that some medications may even exert a protective effect. In addition, 

The SECURE-IBD database is an international, collaborative effort created to monitor COVID-19 outcomes in IBD patients.

Physicians and other health care providers voluntarily reported cases of polymerase chain reaction (PCR)-confirmed, antibody-confirmed, or rapid antigen-confirmed COVID-19 occurring in IBD patients. We instructed health care providers to report cases, regardless of severity, after a minimum of 7 days from symptom onset with sufficient time having passed to observe the disease course through resolution of acute illness or death.

We 

We identified potential duplicate records by matching age, sex, IBD disease type, country, and state (United States only), and confirmed duplicates were excluded. Reports from non-valid email addresses were flagged as potential errors and we performed a Google search of reporters and practice locations to confirm legitimacy of reports (confirmed as being health care providers). If we could not confirm the reporter was a healthcare provider, reports from non-valid email addresses were excluded.

Continuous variables were summarized using means and standard deviations (SDs) and categorical variables using month. We then utilized backward selection for covariates to obtain the most parsimonious models, using a p value of 0.1 as a significance cutoff, with all medication classes of interest being forced into the models. Using an otherwise identical model, we additionally evaluated interaction terms between TNF antagonists and MTX and between TNF antagonists and thiopurines, respectively, using a p value of 0.1 as a significance cutoff.

To further examine the association of different classes of biologic agents with COVID-19 outcomes using an active comparator design, we then restricted our data set to only patients on a biologic (any TNF, IL-12/23, or integrin antagonist)

at the time of COVID-19 infection. We excluded patients on tofacitinib, cyclosporine, and tacrolimus from this analysis. For Finally, to further evaluate the association between mesalamine and COVID-19 severity, we incorporated the covariate mesalamine/sulfasalazine use (versus non-use) into the above biologic-only models. This allowed us to estimate the independent effect of mesalamine in a more homogeneous population of biologic users, while adjusting for the specific biologic agent and other potential confounders.

All data were prepared and analyzed using SAS v 9.3 (SAS Institute, Cary, North Carolina). Two-sided p values ≤ 0.05 were considered statistically significant. All authors had access to the study data and reviewed and approved the final manuscript. J o u r n a l P r e -p r o o f

Effect of IBD medications on COVID-19 outcomes: results from an international registry

Applying the Bradford Hill criteria in the 21st century: how data integration has changed causal inference in molecular epidemiology

Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study

Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease

Once-daily budesonide MMX in active, mildto-moderate ulcerative colitis: results from the randomised CORE II study

Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry

No impact of concomitant methotrexate use on serious adverse event and serious infection risk in patients with rheumatoid arthritis treated with bDMARDs: a systematic literature review and meta-analysis

Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease

AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis